Lapatinib in breast cancer: clinical experiences and future perspectives

被引：17
作者：
Giampaglia, M. [1 ]
Chiuri, V. E.
Tinelli, A. [2 ]
De Laurentiis, M. [3 ,4 ]
Silvestris, N. [5 ]
Lorusso, V.
机构：
[1] Osped Vito Fazzi, Med Oncol Unit, UO Oncologia Med, I-73100 Lecce, Italy
[2] Osped Vito Fazzi, Dept Obstet & Gynaecol, I-73100 Lecce, Italy
[3] Natl Canc Intitute Fdn Pascale, Dept Breast Oncol, Naples, Italy
[4] Univ Naples Federico II, Dept Endocrinol & Mol & Clin Oncol, Naples, Italy
[5] Canc Inst Giovanni Paolo II, Med & Expt Oncol Unit, Bari, Italy
来源：
CANCER TREATMENT REVIEWS | 2010年 / 36卷
关键词：
Breast cancer; EGFR; HER2; Lapatinib; Trastuzumab; Anthracycline; Taxane; Chemotherapy; Tyrosine-kinase inhibitor; DUAL KINASE INHIBITOR; PHASE-II TRIAL; BRAIN METASTASES; GW572016; LAPATINIB; BIOMARKER PROFILES; TYROSINE KINASES; PLUS TRASTUZUMAB; DOSE-ESCALATION; OPEN-LABEL; COMBINATION;
D O I：
10.1016/S0305-7372(10)70024-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Lapatinib, an orally available dual inhibitor targeting the tyrosine-kinase domain of both epidermal growth factor receptor-1 and 2, has been introduced for the treatment of advanced/metastatic HER2+ breast cancer in combination with capacitabine after chemotherapy regimens containing anthracycline, taxanes and trastuzumab. Moreover, lapatinib is under investigation in combination with anthracycline and taxanes in neoadjuvant and adjuvant settings. Another potential field of investigation for this drug is related to its ability to restore hormonal sensitivity of HER2-, hormone-receptor positive breast cancer cells. This paper reviews the current use of lapatinib in breast cancer and its future perspectives. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码：S72 / S79
页数：8
相关论文
共 60 条
[1]  
Adams VR, 2002, P AM SOC CLIN ONCOL, V21
[2]  
[Anonymous], Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study - Full Text View - ClinicalTrials.gov
[3]  
[Anonymous], Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo
[4]   Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer [J].
Blackwell, Kimberly L. ;
Burstein, Harold J. ;
Storniolo, Anna Maria ;
Rugo, Hope ;
Sledge, George ;
Koehler, Maria ;
Ellis, Catherine ;
Casey, Michelle ;
Vukelja, Svetislava ;
Bischoff, Joachim ;
Baselga, Jose ;
O'Shaughnessy, Joyce .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1124-1130
[5]  
Blackwell KL, 2004, J CLIN ONCOL, V22, p196S
[6]  
Brain E, 2009, J CLIN ONCOL, V27
[7]   Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas [J].
Burris, HA ;
Hurwitz, HI ;
Dees, EC ;
Dowlati, A ;
Blackwell, KL ;
O'Neil, B ;
Marcom, PK ;
Ellis, MJ ;
Overmoyer, B ;
Jones, SF ;
Harris, JL ;
Smith, DA ;
Koch, KM ;
Stead, A ;
Mangum, S ;
Spector, NL .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5305-5313
[8]   A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses [J].
Cameron, David ;
Casey, Michelle ;
Press, Michael ;
Lindquist, Deborah ;
Pienkowski, Tadeusz ;
Romieu, C. Gilles ;
Chan, Stephen ;
Jagiello-Gruszfeld, Agnieszka ;
Kaufman, Bella ;
Crown, John ;
Chan, Arlene ;
Campone, Mario ;
Viens, Patrice ;
Davidson, Neville ;
Gorbounova, Vera ;
Raats, Johannes Isaac ;
Skarlos, Dimosthenis ;
Newstat, Beth ;
Roychowdhury, Debasish ;
Paoletti, Paolo ;
Oliva, Cristina ;
Rubin, Stephen ;
Stein, Steven ;
Geyer, Charles E. .
BREAST CANCER RESEARCH AND TREATMENT, 2008, 112 (03) :533-543
[9]  
Chu I, 2005, CANCER RES, V65, P18
[10]   A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer [J].
Chu, Quincy S. C. ;
Cianfrocca, Mary E. ;
Goldstein, Lori J. ;
Gale, Meg ;
Murray, Nicholas ;
Loftiss, Jill ;
Arya, Nikita ;
Koch, Kevin M. ;
Pandite, Lini ;
Fleming, Ronald A. ;
Paul, Elaine ;
Rowinsky, Eric K. .
CLINICAL CANCER RESEARCH, 2008, 14 (14) :4484-4490
123456